Since its establishment in 1972, Novum Pharmaceutical Research Services has consistently contributed to the advancement of clinical research through operational excellence and scientific rigor. The formation of the Novum Independent Review Board in 1992 marked a significant enhancement to its ethical oversight framework, reinforcing its focus on patient safety and regulatory compliance.
The acquisition by Lambda Therapeutic Research in 2019 positioned Novum within a global network, broadening its operational footprint and strengthening its service offerings. By 2020, the integration of Lambda’s Toronto facility further enhanced Novum’s delivery infrastructure, enabling a unified platform for comprehensive clinical research services across North America and beyond.
In 2025, the launch of Novum Therapeutics SL in Spain marked a strategic extension into Southern Europe, strengthening the company’s global service continuum.